DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 93 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Aurobindo Pharma Limited — Sale or disposal-XBRL

NSE 1 hr ago·1 Oct 2026, 9:01 am

Aurobindo Pharma

Aurobindo Pharma has informed stock exchanges about its intention to sell or dispose of a unit, division, or subsidiary. The company has filed XBRL data to disclose this corporate action, though specific details regarding the asset or the buyer are not yet public.

For investors, this move could signal a strategic shift, such as focusing on core strengths or unlocking value from non-core assets. It may also impact the company's financials, including revenue and profitability, depending on the size and performance of the business being sold.

Investors should watch for the company's future announcements to identify the specific business unit involved. Following the completion of the deal, market participants will assess its impact on Aurobindo's growth strategy and overall financial health.